MUMBAI, India, July 5 -- Intellectual Property India has published a patent application (202517059478 A) filed by Segena Corporation S. A., Montevideo, Uruguay, on June 20, for 'enhancing oligonucleotide immunomodulatory activity through dianophore long-lasting modification: methods and applications.'
Inventor(s) include Bosi, Susanna; and Tisminetzky, Sergio Gabriel.
The application for the patent was published on July 4, under issue no. 27/2025.
According to the abstract released by the Intellectual Property India: "Dianophore Long-Lasting Modifications ooff oligonucleotides with immunomodulatory and homeostatic properties (including the proliferation of pluripotent mesenchymal stem cells (MSC) of animals, including humans). Different ONs were synthetized with a modification at their backbone structure and chemically combined with some specific organic molecules, modifying the original dianophore (but not the pharmacophore) of the original ON, yielding several long-lasting conjugates. The obtained conjugates are not susceptible to in vivo hydrolytic cleavage and have enhanced in vivo half-life, also in its natural phosphodiester form and have shown much more biological potency (hundred to thousand times). These modified oligonucleotides are used in a wide range of clinical treatments involving the immune system and/or regeneration of mesenchymal tissues which have been damaged through acute injury, abnormal genetic expression or acquired disease. In addition, relates to the impact of LLONC (Long-lasting Oligonucleotide Conjugates) inoculation, having biologically active oligonucleotides (phosphodiester or partially/fully phosphorothioated) with various dianophore modifications."
The patent application was internationally filed on Nov. 20, 2023, under International application No.PCT/IB2023/061699.
Disclaimer: Curated by HT Syndication.
